This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rust, D. M. Articles by Soignet, S. L. Search for Related Content PubMed PubMed Citation Articles by Rust, D. M. Articles by Soignet, S. L.

Risk/Benefit Profile of Arsenic Trioxide

^a Acute Care Nurse Practitioner Program (Oncology Subspecialty), School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; ^b Memorial Sloan-Kettering Cancer Center and Department of Medicine, and the Joan and Sanford Weill Medical College of Cornell University, New York, New York, USA

Correspondence: Steven L. Soignet, M.D., Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021-6007, USA. Telephone: 212-639-8984; Fax: 212-717-3172; e-mail: soignets{at}mskcc.org

Approximately 20%-30% of patients with acute promyelocytic leukemia (APL) who are treated with the current standard all-trans retinoic acid and anthracycline-based chemotherapy regimen suffer relapse. In the mid-1990s, studies from China reported the effective use of arsenic trioxide in achieving complete remission in patients with APL. In the United States, a multicenter trial of this agent in 40 patients with relapsed APL following conventional therapy confirmed the positive safety and efficacy outcomes of a smaller 12-patient pilot study. Common adverse events were hyperleukocytosis, APL differentiation syndrome, prolonged QT interval on electrocardiogram, skin rash, and hyperglycemia.

Key Words. Arsenic trioxide • Acute promyelocytic leukemia • All-trans retinoic acid • APL differentiation syndrome • Hyperleukocytosis • QT interval

This article has been cited by other articles:

				A. M. Tsimberidou, L. H. Camacho, S. Verstovsek, C. Ng, D. S. Hong, C. K. Uehara, C. Gutierrez, S. Daring, J. Stevens, P. B. Komarnitsky, et al. A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors Clin. Cancer Res., July 15, 2009; 15(14): 4769 - 4776. [Abstract] [Full Text] [PDF]

				P. Phatak, F. Dai, M. Butler, M.P. Nandakumar, P. L. Gutierrez, M. J. Edelman, H. Hendriks, and A. M. Burger KML001 Cytotoxic Activity Is Associated with Its Binding to Telomeric Sequences and Telomere Erosion in Prostate Cancer Cells Clin. Cancer Res., July 15, 2008; 14(14): 4593 - 4602. [Abstract] [Full Text] [PDF]

				H.-Y. Jiang, L. Jiang, and R. C. Wek The Eukaryotic Initiation Factor-2 Kinase Pathway Facilitates Differential GADD45a Expression in Response to Environmental Stress J. Biol. Chem., February 9, 2007; 282(6): 3755 - 3765. [Abstract] [Full Text] [PDF]

				T. A. Rich, R. C. Shepard, and S. T. Mosley Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232. [Abstract] [Full Text] [PDF]

				B. Drolet, C. Simard, and D. M. Roden Unusual Effects of a QT-Prolonging Drug, Arsenic Trioxide, on Cardiac Potassium Currents Circulation, January 6, 2004; 109(1): 26 - 29. [Abstract] [Full Text] [PDF]

				G. Pentheroudakis and N. Pavlidis Immunomodulation in colorectal cancer: disappointment or promise? Ann. Onc., March 1, 2003; 14(3): 349 - 351. [Full Text] [PDF]